Form 4: LENZ Therapeutics Director Receives Stock Option Grant

Director Shelley B. Thunen was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's compensation policy.

Summary

• Director Shelley B. Thunen received a grant of 22,100 stock options on June 15, 2026.
• The options have an exercise price of $6.63 per share.
• The options are scheduled to vest in full on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service as an Outside Director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director maintaining their status as an Outside Director through the vesting period.

Future Outlook

The options vest in one year, aligning the director's tenure with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with long-term corporate performance.

Comparison to Industry Standards

• The grant structure follows standard industry practices for director compensation in small-cap biotech firms.
• Vesting periods of one year are consistent with typical annual equity refresh cycles for board members.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 15, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Form 4, Insider Trading, Stock Options, Director Compensation